Management of Severe Infant Atopic Dermatitis

Initial Therapeutic Approach

Start treatment with liberal, fragrance‑free emollient use (≥2 applications daily, 200–400 g / week) applied immediately after a lukewarm bath, combined with low‑potency topical corticosteroid (hydrocortisone 1 %) for active lesions. If adequate control is not achieved within 1–2 weeks, add a topical calcineurin inhibitor (pimecrolimus 1 % for infants ≥ 3 months) or refer for systemic options. 1

Apply low‑potency hydrocortisone 1 % once or twice daily to inflamed areas for a short course of 3–7 days, then reassess. Prolonged daily use beyond 7 days without review is discouraged. 1
After the acute course, switch to proactive maintenance with twice‑weekly applications on previously affected skin to prevent rebound flares. 1
Avoid medium, high, or ultra‑high potency steroids in infants because of a markedly increased risk of hypothalamic‑pituitary‑adrenal axis suppression due to their high surface‑area‑to‑volume ratio. 1
Use extreme caution when applying steroids to the face, neck, and skin folds; prefer non‑steroidal agents for these sensitive sites. 1

Pimecrolimus 1 % cream is FDA‑approved for infants ≥ 3 months and is especially useful for facial eczema as a steroid‑sparing option. 1
Tacrolimus 0.03 % ointment is FDA‑approved for children ≥ 2 years and can be used on the face and genital area when steroids are unsuitable. 1
Both calcineurin inhibitors avoid corticosteroid‑related adverse effects such as skin atrophy and HPA‑axis suppression. 1

If secondary bacterial infection is suspected (crusting, weeping, or worsening despite therapy), treat presumptively with oral flucloxacillin as first‑line therapy for Staphylococcus aureus. 1
For eczema herpeticum (herpes simplex infection), initiate oral acyclovir promptly to prevent rapid systemic spread. 1

Dupilumab (DUPIXENT) is FDA‑approved for infants ≥ 6 months with moderate‑to‑severe atopic dermatitis uncontrolled by topical agents. Clinical trial data show a 69.7 % rate of EASI‑75 improvement after 16 weeks in children 6–11 years. Evidence level: high‑quality randomized trial. 1
Common dupilumab adverse events include conjunctivitis, facial erythema, injection‑site reactions, and herpes simplex infection. 1
Short‑course oral corticosteroids (< 7 days) may be used for severe acute flares, but recent evidence indicates an increased risk of serious adverse events even with brief exposure; rebound flares are common after abrupt cessation. 1

Refer to a pediatric dermatologist when low‑potency steroid therapy fails to achieve control within 1–2 weeks of appropriate use. [2][3]
Refer when second‑line topical agents or dietary manipulation are being considered, or when diagnostic uncertainty exists. [2][3]

Evening primrose oil has shown no benefit in two large trials; it should not be recommended. [2][3]
Homeopathic remedies lack scientific evidence of efficacy and are not advised. [2][3]
Chinese herbal medicines carry a risk of hepatotoxicity and require routine liver‑function monitoring; they are not recommended as routine therapy. [2][3]
Dietary elimination should be reserved for cases with a clear history of food‑allergy‑driven eczema or when first‑line treatments have failed. [2][3]

Do not continue daily topical corticosteroid application beyond 7 days without reassessment; transition to twice‑weekly maintenance instead. 1
Do not use potent or ultra‑potent steroids as first‑line therapy in infants because of the high risk of systemic absorption. 1
Do not abruptly stop corticosteroids; taper to proactive maintenance to prevent rebound flares. 1
Do not delay treatment of secondary infection, as bacterial superinfection markedly worsens disease control. 1

The American Academy of Pediatrics recommends regular emollients applied liberally at least twice daily plus low-potency topical corticosteroids (hydrocortisone 1%) for flares as the cornerstone of eczema management in babies 4, 5, 6
Apply emollients liberally and frequently—at least twice daily and as needed throughout the day to maintain barrier function 6
Ointments and creams are suitable for very dry skin or winter use, and should be applied immediately after bathing to lock in moisture when skin is most hydrated 5

Use low-potency corticosteroids only (hydrocortisone 1%) for infants and babies, and apply once or twice daily to affected areas until lesions significantly improve 5, 7, 8
Avoid high-potency or ultra-high-potency corticosteroids in infants due to increased risk of hypothalamic-pituitary-adrenal axis suppression from their high body surface area-to-volume ratio 7, 8

Pimecrolimus 1% cream is FDA-approved for babies as young as 3 months and is particularly useful for facial eczema, as a steroid-sparing alternative 4, 8
Tacrolimus 0.03% ointment is approved for children aged 2 years and above, and is also a steroid-sparing alternative especially valuable for face and genital regions 5, 8

Watch for crusting, weeping, or worsening despite treatment, which may indicate secondary bacterial infection, and treat with flucloxacillin as first-choice antibiotic for Staphylococcus aureus infections 6, 7, 8
Avoid long-term topical antibiotics due to resistance and sensitization risk, and use oral acyclovir for eczema herpeticum (herpes simplex infection) 4, 7, 8

Sedating antihistamines may help short-term for sleep disturbance caused by itching, primarily at night, but non-sedating antihistamines have little value in atopic eczema 6, 7, 8
Use cotton clothing next to skin and avoid wool or synthetic fabrics, and keep fingernails short to minimize scratching damage 6, 7, 8

Never use high-potency corticosteroids on infants—risk of systemic absorption and HPA axis suppression is significantly elevated, and provide only limited quantities with specific instructions on safe application sites 7, 8
Monitor for skin atrophy, striae, or signs of systemic absorption, and avoid abrupt discontinuation of corticosteroids to prevent rebound flares 6, 7